Keros Therapeutics, Inc. (KROS)
NASDAQ·Healthcare·Biotechnology
$11.38
+3.36%
Mkt Cap $428.42M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Mar 4, 2026 | $3.67M | $385.00K | -89.50% | -$0.49 | -$0.86 | -75.51% | — | — |
| Q4 2025 Nov 5, 2025 | $3.66M | $14.26M | +289.41% | -$1.11 | -$0.18 | +83.78% | — | — |
| Q3 2025 Aug 6, 2025 | $3.21M | $18.17M | +465.88% | -$1.14 | -$0.76 | +33.33% | — | — |
| Q2 2025 May 6, 2025 | $56.65M | $211.25M | +272.93% | -$0.01 | $3.62 | +36300.00% | — | — |
| Q1 2025 Feb 26, 2025 | $22.23M | $3.04M | -86.32% | -$1.36 | -$1.14 | +16.18% | — | — |
| Q4 2024 Nov 6, 2024 | $2.31M | $388.00K | -83.20% | -$1.26 | -$1.41 | -11.90% | — | — |
| Q3 2024 Aug 7, 2024 | — | $37.00K | — | -$1.23 | -$1.25 | -1.63% | — | — |
| Q2 2024 May 8, 2024 | — | $83.00K | — | -$1.31 | -$1.21 | +7.63% | — | — |
| Q1 2024 Feb 28, 2024 | — | $143.00K | — | -$1.38 | -$1.34 | +2.90% | — | — |
| Q4 2023 Nov 6, 2023 | — | $8.00K | — | -$1.34 | -$1.33 | +0.75% | — | — |
| Q3 2023 Aug 7, 2023 | $160.00K | — | — | -$1.34 | -$1.27 | +5.22% | — | — |
| Q2 2023 May 4, 2023 | $220.00K | — | — | -$1.13 | -$1.26 | -11.50% | — | — |
| Q1 2023 Mar 3, 2023 | $1.20M | — | — | -$1.12 | -$1.09 | +2.68% | — | — |
| Q4 2022 Nov 3, 2022 | — | — | — | -$1.26 | -$0.92 | +26.98% | — | — |
| Q3 2022 Aug 4, 2022 | — | $100.00K | — | -$1.07 | -$1.13 | -5.61% | — | — |
| Q2 2022 May 5, 2022 | $6.00M | — | — | -$0.86 | -$1.01 | -17.44% | — | — |
| Q1 2022 Mar 9, 2022 | — | $20.00M | — | -$0.94 | -$0.30 | +68.09% | — | — |
| Q4 2021 Nov 4, 2021 | — | — | — | -$0.72 | -$0.87 | -20.83% | — | — |
| Q3 2021 Aug 5, 2021 | $100.00K | $100.00K | +0.00% | -$0.66 | -$0.67 | -1.52% | — | — |
| Q2 2021 May 6, 2021 | — | — | — | -$0.58 | -$0.68 | -17.24% | — | — |